CelluTarget · Multifocal Motor Neuropathy · Clinical Trials
Phase 3
Recruiting

MK-0616 (oral PCSK9 inhibitor)

Sponsored by Merck ↗
Timeline
Study Dates
Start Date
January 2024
Est. Completion
December 2030
Enrollment Target
17000 participants
Status
Recruiting
Study Design
Primary Endpoint
MACE composite: CV death, non-fatal MI, non-fatal stroke requiring revascularization
⚠ No ClinicalTrials.gov registry ID found for this program. This trial was announced but no registered study has been identified. CelluTarget flags this distinction rather than treating announced and registered trials as equivalent.
Related Treatment
Treatment Being Studied
MK-0616 (oral PCSK9 inhibitor) →